MX2020002921A - Anticuerpos para claudin6 y métodos para tratar el cáncer. - Google Patents
Anticuerpos para claudin6 y métodos para tratar el cáncer.Info
- Publication number
- MX2020002921A MX2020002921A MX2020002921A MX2020002921A MX2020002921A MX 2020002921 A MX2020002921 A MX 2020002921A MX 2020002921 A MX2020002921 A MX 2020002921A MX 2020002921 A MX2020002921 A MX 2020002921A MX 2020002921 A MX2020002921 A MX 2020002921A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- antigen
- claudin6
- antibodies
- treat cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762560143P | 2017-09-18 | 2017-09-18 | |
| PCT/US2018/051610 WO2019056023A2 (en) | 2017-09-18 | 2018-09-18 | ANTIBODIES AGAINST CLAUDIN 6 AND METHODS OF TREATING CANCER |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002921A true MX2020002921A (es) | 2020-09-28 |
Family
ID=65723110
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002921A MX2020002921A (es) | 2017-09-18 | 2018-09-18 | Anticuerpos para claudin6 y métodos para tratar el cáncer. |
| MX2025012685A MX2025012685A (es) | 2017-09-18 | 2020-03-17 | Anticuerpos para claudin6 y metodos para tratar el cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025012685A MX2025012685A (es) | 2017-09-18 | 2020-03-17 | Anticuerpos para claudin6 y metodos para tratar el cancer |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US20200291111A1 (enExample) |
| EP (2) | EP4435009A3 (enExample) |
| JP (2) | JP7599332B2 (enExample) |
| KR (2) | KR102793719B1 (enExample) |
| CN (2) | CN118667021A (enExample) |
| AU (2) | AU2018334434B2 (enExample) |
| BR (1) | BR112020005196A2 (enExample) |
| CA (1) | CA3076207A1 (enExample) |
| CZ (1) | CZ2021138A3 (enExample) |
| DK (1) | DK3826667T3 (enExample) |
| ES (1) | ES2986343T3 (enExample) |
| FI (1) | FI3826667T3 (enExample) |
| GB (1) | GB202103867D0 (enExample) |
| HU (1) | HUE067603T2 (enExample) |
| IL (2) | IL313238A (enExample) |
| MX (2) | MX2020002921A (enExample) |
| NO (1) | NO20210351A1 (enExample) |
| PL (1) | PL3826667T3 (enExample) |
| PT (1) | PT3826667T (enExample) |
| SG (1) | SG11202002114RA (enExample) |
| SI (1) | SI3826667T1 (enExample) |
| WO (1) | WO2019056023A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118667021A (zh) * | 2017-09-18 | 2024-09-20 | 加利福尼亚大学董事会 | 紧密连接蛋白6抗体和治疗癌症的方法 |
| AU2018342527B2 (en) | 2017-09-29 | 2024-06-27 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| KR102063341B1 (ko) * | 2018-12-31 | 2020-01-07 | 다이노나(주) | Icam-1에 특이적으로 결합하는 항체 및 그의 용도 |
| CA3129834A1 (en) | 2019-02-15 | 2020-08-20 | Integral Molecular, Inc. | Claudin 6 antibodies and uses thereof |
| EP3941944A4 (en) * | 2019-03-20 | 2022-11-30 | The Regents of the University of California | Claudin-6 bispecific antibodies |
| BR112021018608A2 (pt) * | 2019-03-20 | 2021-11-23 | Univ California | Anticorpos para claudina-6 e conjugados de fármaco |
| WO2021225954A1 (en) | 2020-05-04 | 2021-11-11 | The Regents Of The University Of California | Inhibiting anti-enpp1 antibodies |
| CN112386687B (zh) * | 2020-12-09 | 2021-05-04 | 爱龄医美国际健康咨询服务(北京)有限公司 | 一种干细胞外泌体及其在药品和化妆品中的应用 |
| WO2023091512A2 (en) * | 2021-11-16 | 2023-05-25 | Allakos, Inc. | Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9 |
| JP2025508362A (ja) * | 2022-02-09 | 2025-03-26 | セラ プログノスティックス， インコーポレイテッド | Ｓｈｂｇおよびｉｂｐ４抗体、ならびにそれを使用する方法 |
| EP4626933A1 (en) | 2022-11-30 | 2025-10-08 | Integral Molecular, Inc. | Antibodies directed to claudin 6, including bispecific formats thereof |
| WO2024243561A1 (en) | 2023-05-25 | 2024-11-28 | The Regents Of The University Of California | Methods of treating cancer |
| WO2025075127A1 (ja) * | 2023-10-04 | 2025-04-10 | 公立大学法人福島県立医科大学 | がんのバイオマーカー及び抗体治療 |
| WO2025146161A1 (en) * | 2024-01-04 | 2025-07-10 | Hansoh Bio Llc | Antibody, antigen-binding fragment and medical use thereof |
| WO2025162270A1 (zh) * | 2024-02-01 | 2025-08-07 | 江苏恒瑞医药股份有限公司 | 抗cldn6抗体、其抗体-药物偶联物及其医药用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4450150A (en) | 1973-05-17 | 1984-05-22 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery depots, and method for preparing and using the same |
| US4526988A (en) | 1983-03-10 | 1985-07-02 | Eli Lilly And Company | Difluoro antivirals and intermediate therefor |
| DE3587500T2 (de) | 1984-12-04 | 1993-12-16 | Lilly Co Eli | Tumorbehandlung bei Säugetieren. |
| CN1296417A (zh) | 1998-02-10 | 2001-05-23 | 卫福有限公司 | 控释制剂 |
| US6630124B1 (en) | 1998-10-16 | 2003-10-07 | Ramot-University Authority For Applied Research And Industrial Development Ltd. | Combination therapy with VIP antagonist |
| GB2344287A (en) | 1998-12-03 | 2000-06-07 | Ferring Bv | Controlled release pharmaceutical formulation |
| EP1257289A1 (en) | 2000-02-08 | 2002-11-20 | The Penn State Research Foundation | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
| ATE395413T1 (de) | 2001-12-03 | 2008-05-15 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
| AU2003279842A1 (en) | 2002-10-04 | 2004-05-04 | Microchips, Inc. | Medical device for controlled drug delivery and cardiac monitoring and/or stimulation |
| AU2007332473B2 (en) * | 2006-12-14 | 2012-09-27 | Forerunner Pharma Research Co., Ltd. | Anti-Claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same |
| EP2139458A4 (en) | 2007-04-19 | 2013-01-23 | Dong A Pharm Co Ltd | COMPOSITION OF BIODEGRADABLE MICROSPHERES WITH CONTROLLED RELEASE OF A GLUCOSE REGULATING PEPTIDE AND RELATED FORMULA |
| AU2009203464A1 (en) * | 2008-01-11 | 2009-07-16 | Forerunner Pharma Research Co., Ltd. | Anti-CLDN6 antibody |
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| AU2012258087B2 (en) * | 2011-05-13 | 2017-07-20 | Astellas Pharma Inc. | Antibodies for treatment of cancer expressing claudin 6 |
| WO2015014376A1 (en) * | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| RU2016122041A (ru) * | 2013-11-06 | 2017-12-11 | ЭББВИ СТЕМСЕНТРКС ЭлЭлСи | Новые анти-клаудин антитела и способы их применения |
| DK3708579T3 (da) * | 2014-04-01 | 2024-07-22 | Biontech Cell & Gene Therapies Gmbh | Claudin-6-specifikke immunreceptorer og t-celleepitoper |
| CN118667021A (zh) * | 2017-09-18 | 2024-09-20 | 加利福尼亚大学董事会 | 紧密连接蛋白6抗体和治疗癌症的方法 |
-
2018
- 2018-09-18 CN CN202410853420.8A patent/CN118667021A/zh active Pending
- 2018-09-18 WO PCT/US2018/051610 patent/WO2019056023A2/en not_active Ceased
- 2018-09-18 ES ES18857242T patent/ES2986343T3/es active Active
- 2018-09-18 KR KR1020207009742A patent/KR102793719B1/ko active Active
- 2018-09-18 IL IL313238A patent/IL313238A/en unknown
- 2018-09-18 CA CA3076207A patent/CA3076207A1/en active Pending
- 2018-09-18 GB GBGB2103867.4A patent/GB202103867D0/en active Pending
- 2018-09-18 EP EP24169481.9A patent/EP4435009A3/en active Pending
- 2018-09-18 NO NO20210351A patent/NO20210351A1/en not_active Application Discontinuation
- 2018-09-18 MX MX2020002921A patent/MX2020002921A/es unknown
- 2018-09-18 EP EP18857242.4A patent/EP3826667B1/en active Active
- 2018-09-18 DK DK18857242.4T patent/DK3826667T3/da active
- 2018-09-18 FI FIEP18857242.4T patent/FI3826667T3/fi active
- 2018-09-18 SG SG11202002114RA patent/SG11202002114RA/en unknown
- 2018-09-18 SI SI201831128T patent/SI3826667T1/sl unknown
- 2018-09-18 JP JP2020515692A patent/JP7599332B2/ja active Active
- 2018-09-18 KR KR1020257011014A patent/KR20250050137A/ko active Pending
- 2018-09-18 HU HUE18857242A patent/HUE067603T2/hu unknown
- 2018-09-18 BR BR112020005196-9A patent/BR112020005196A2/pt unknown
- 2018-09-18 PT PT188572424T patent/PT3826667T/pt unknown
- 2018-09-18 AU AU2018334434A patent/AU2018334434B2/en active Active
- 2018-09-18 PL PL18857242.4T patent/PL3826667T3/pl unknown
- 2018-09-18 US US16/648,428 patent/US20200291111A1/en not_active Abandoned
- 2018-09-18 CN CN201880073220.3A patent/CN111565744B/zh active Active
- 2018-09-18 IL IL273196A patent/IL273196B2/en unknown
-
2020
- 2020-03-17 MX MX2025012685A patent/MX2025012685A/es unknown
-
2021
- 2021-03-19 CZ CZ2021138A patent/CZ2021138A3/cs unknown
-
2022
- 2022-04-13 US US17/719,609 patent/US20220372134A1/en not_active Abandoned
-
2023
- 2023-12-19 US US18/545,890 patent/US20240400674A1/en not_active Abandoned
-
2024
- 2024-06-20 JP JP2024099523A patent/JP2024150445A/ja active Pending
-
2025
- 2025-01-23 AU AU2025200467A patent/AU2025200467A1/en active Pending
- 2025-06-27 US US19/252,512 patent/US20250333501A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
| BR112022000371A2 (pt) | Anticorpos claudin18 e métodos de tratamento contra câncer | |
| AR115389A1 (es) | Anticuerpo antagonista de cd73 | |
| DOP2019000011A (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
| MX2022006760A (es) | Composiciones de proteina anti-vegf y metodos para producir la misma. | |
| EA201892616A1 (ru) | Антитела к pd1 и lag3 для лечения злокачественного новообразования | |
| CL2019002310A1 (es) | Receptores quiméricos y métodos de uso de los mismos (divisional solicitud 201802797) | |
| MX2022015901A (es) | Proteinas de union biespecificas y usos de las mismas. | |
| MX389710B (es) | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos. | |
| EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
| UY36536A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| MX2021011330A (es) | Anticuerpos de claudina-6 y conjugados de fármacos. | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| AR105444A1 (es) | Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3) | |
| EA201892312A1 (ru) | Триспецифические и/или тривалентные связывающие белки | |
| CR20210225A (es) | RECEPTORES DE ANTÍGENES QUIMÉRICOS BASADOS EN ANTICUERPOS DE DOMINIO SIMPLE Y MÉTODOS DE USO DE ESTOS (Divisional 2018-0153) | |
| EA201991912A1 (ru) | Составы, содержащие pd-1-связывающие белки, и способы их получения | |
| CO2020001654A2 (es) | Proteínas de fijación al antígeno que se fijan a 5t4 y 4-1bb y composiciones y métodos relacionados | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| PH12019502449A1 (en) | Anti-jagged1 antigen binding proteins | |
| MX2023012707A (es) | Anticuerpos de la proteina inmunorreceptora de celulas t con dominios ig e itim (anti-tigit) y metodos de uso de estos. | |
| EA202091596A1 (ru) | Антитела к pd-1 и способы лечения | |
| EA201990927A1 (ru) | Антитела против lag-3 и способы их применения | |
| EA201792665A1 (ru) | Антитела против ctla-4 и способы их применения | |
| EA201992747A1 (ru) | Антитела к fam19a5 и их применение |